Lyra Therapeutics, Inc. Board of Directors

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Dr. Maria Palasis Ph.D.

Dr. Maria Palasis Ph.D.

CEO, President & Director

Dr. Robert Richard Ph.D.

Dr. Robert Richard Ph.D.

Senior Vice President of Technical Operations

Mr. Ray Knox

Mr. Ray Knox

Vice President of Operations

Ms. Gloria Cosgrove

Ms. Gloria Cosgrove

Senior Vice President of Quality

Ms. Vineeta Belanger Ph.D.

Ms. Vineeta Belanger Ph.D.

Senior Vice President of Clinical Affairs

Dr. Robert Kern M.D.

Dr. Robert Kern M.D.

Chief Clinical Advisor

Mr. Jason Cavalier

Mr. Jason Cavalier

CFO, Treasurer & Secretary

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.